anacetrapib

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Heart DiseaseHypercholesterolemiaFamilial HypercholesterolemiaHomozygous Familial Hypercholesterolemia

166 competitors in Heart Disease

#DrugCompanyPhaseTrials

1

Aldactone

Pfizer

Phase 3

12

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

93

Biaxin

AbbVie

Phase 3

14

Ozempic

Novo Nordisk

Phase 3

15

Depo-Provera

Eli Lilly

Phase 3

—6

Activella

Eli Lilly

Phase 3

—7

Vivarin

HHikma Pharmaceuticals LLC

Phase 3

18

Levophed

GGeneral Hospital of Ningxia Medical University

Phase 3

—9

Comparator: Statins

Merck & Co.

Phase 3

110

Zesly

MMezzion Pharma Co. Ltd

Phase 3

—Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Safety and Efficacy3 trials

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Completed·Merck & Co.·Phase 2·NCT00977288·408 enrolled

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Completed·Merck & Co.·Phase 3·NCT01760460·307 enrolled

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Completed·Merck & Co.·Phase 3·NCT01717300·459 enrolled

Familial Hypercholesterolemia2 trials

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Completed·Merck & Co.·Phase 3·NCT01524289·306 enrolled

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Completed·Merck & Co.·Phase 3·NCT01824238·68 enrolled

Heart Disease1 trial

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

Completed·Merck & Co.·Phase 3·NCT00685776·1,623 enrolled

Dyslipidemia1 trial

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Completed·Merck & Co.·Phase 1·NCT00990808·46 enrolled

Homozygous Familial Hypercholesterolemia1 trial

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

Terminated·Merck & Co.·Phase 3·NCT01841684·2 enrolled

5 more indications

Arterial Stiffness1 trial

The Effect of Anacetrapib on Vascular Function and Arterial Stiffness

Completed·—··NCT02931188·103 enrolled

Hepatic Insufficiency1 trial

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Completed·Merck & Co.·Phase 1·NCT01114490·24 enrolled

Hypercholesterolemia1 trial

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Completed·Merck & Co.·Phase 3·NCT01860729·589 enrolled

Randomized1 trial

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Active, not recruiting·UUniversity of Oxford·Phase 3·NCT01252953·30,449 enrolled

Impaired Renal Function1 trial

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Completed·Merck & Co.·Phase 1·NCT01122667·24 enrolled

Details

Drug Info

Related News